Zhaoru Gu

Zhaoru Gu

Auto-generated profile, based on publicly available information

Zhaoru Gu

State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2023 in Cancer Innovation
Verified
Journal Article
Open access
ZGZhaoru Gu
Zhaoru Gu
QWQuanyou Wu
Quanyou Wu
BSBingqing Shang
Bingqing Shang
KZKaitai Zhang
Kaitai Zhang
WZWen Zhang
Wen Zhang
In recent years, the three‐dimensional (3D) culture system has emerged as a promising preclinical model for tumor research owing to its ability to replicate the tissue structure and molecular characteristics of solid tumors in vivo. This system offers several advantages, including high throughput, efficiency, and retention of tumor heterogeneity. Traditional Matrigel‐submerged organoid cultures primarily support the long‐term proliferation of epithelial cells. One solution for the exploration of the tumor microenvironment is a reconstitution approach involving the introduction of exogenous cell types, either in dual, triple or even multiple combinations. Another solution is a holistic approach including patient‐derived tumor fragments, air‐liquid interface, suspension 3D culture, and microfluidic tumor‐on‐chip models. Organoid co‐culture models have also gained popularity for studying the tumor microenvironment, evaluating tumor immunotherapy, identifying predictive biomarkers, screening for effective drugs, and modeling infections. By leveraging these 3D culture systems, it is hoped to advance the clinical application of therapeutic approaches and improve patient outcomes.

1 October 2020 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YZYuou Zhang
Yuou Zhang
XLXuan Liu
Xuan Liu
LYLinghe Yang
Linghe Yang
GZGuifang Zhang
Guifang Zhang
ZGZhaoru Gu
Zhaoru Gu
JSJing SUN
Jing SUN
This study analyzed the barriers of patient access to affordable MDR-TB medication in China and the reasons behind, and proposed strategies towards removing the barriers based on literature review and key informant interviews. Reasons behind the high financial burden of MDR-TB patients in China are the lack of a coordinated and multi-sourced financing model to secure patients’ access to the expensive novel medicines, and the absence of the safety-net for the patients with low ability to pay the costs. Appropriate health insurance benefit packages and provider payment mechanisms, supportive legal framework, coordinated policies as well as incentives for off-label use of evidence-based repurposed medicines are missing. The observations identified key intervention areas including continued efforts to make the novel effective medicines affordable and to strengthen the legislative protection for off-label use of evidence-based medicines; increase incentives for pharmaceutical companies to expand indications of established medicines based on the evidence; implement public initiatives to support the use of repurposed medicines for diseases with major public health significance, and scale up good practices from local pilots to create a coordinated multi-sourced financing model. A comprehensive approach to address the barriers in the full treatment course of MDR-TB and a safety-net for low-ability-to-pay patients are also critical to secure universal access to affordable MDR-TB medication.